Search Results - "Moore, Amy Patricia"

A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies by Moore, Amy Patricia, Truong, Thach-Giao, Thurn, Kenneth Ted, Thomas, Scott, Ryan, Charles J., Jahan, Thierry Marie, DuBois, Steven G., Chan, John K., Rugo, Hope S., Collisson, Eric Andrew, Raha, Paromita, Chen, Stephanie, Reinert, Anne, Daud, Adil, Munster, Pamela N.

“…Abstract only 3058 Background: Preclinical and clinical data suggest pre-exposure of cancer cells to a histone deacetylase inhibitor (HDACi) potentiates…”
Get full text

Phase Ib study of the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) in combination with bevacizumab (bev) with or without paclitaxel by Goldman, Jonathan Wade, Gordon, Michael S., Munster, Pamela N., Bergsland, Emily K., Moore, Amy Patricia, Bai, Shuang, Hegde, Priti, Fredrickson, Jill O., Chang, Ilsung, Chandler, G. Scott, Funke, Roel Peter, Rhee, Ina Park, Chen, Daniel S., Rosen, Lee S.

“…Abstract only e13000 Background: Epidermal growth factor-like domain 7 (EGFL7), is a vascular-restricted, tumor selective, extracellular matrix protein that…”
Get full text